Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trial
- 31 March 2005
- journal article
- clinical trial
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 52 (3), 425-433
- https://doi.org/10.1016/j.jaad.2004.09.029
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Subcutaneously Administered Efalizumab (Anti-CD11a) Improves Signs and Symptoms of Moderate to Severe Plaque PsoriasisJournal of Cutaneous Medicine and Surgery, 2003
- The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibodyJournal of the American Academy of Dermatology, 2001
- Treatment of psoriasis. Part 2. Systemic therapiesJournal of the American Academy of Dermatology, 2001
- Anti-CD11a treatment for psoriasis concurrently increases circulating T-cells and decreases plaque T-cells, consistent with inhibition of cutaneous T-cell trafficking.Journal of Investigative Dermatology, 2000
- The Immunological Synapse: A Molecular Machine Controlling T Cell ActivationScience, 1999
- An approach to the treatment of moderate to severe psoriasis with rotational therapyJournal of the American Academy of Dermatology, 1993
- Role of Lymphocyte Adhesion Receptors in Transient Interactions and Cell LocomotionAnnual Review of Immunology, 1991
- Leukocyte membrane adhesion proteins LFA-1, CR3 and p150,95: A review of functional and regulatory aspectsResearch in Immunology, 1989
- Lymphocyte function-associated antigen-1 (LFA-1) interaction with intercellular adhesion molecule-1 (ICAM-1) is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cells.The Journal of cell biology, 1988
- The Lymphocyte Function Associated LFA-1, CD2, and LFA-3 Molecules: Cell Adhesion Receptors of the Immune SystemAnnual Review of Immunology, 1987